Cohort 8.0 founders Garland Surgical have been awarded up to €1.4 million in grant funding by Malta Enterprise.

We are incredibly excited to bring you some fantastic news from Cohort 8.0 founders Garland Surgical. Garland, who are developing a revolutionary longer-lasting hip replacement - the MaltaHip have been approved for up to €1.4 million in grant funding by Malta Enterprise - the economic development agency for Malta.

Aimed at helping Garland push the MaltaHip towards regulatory approval and market launch, Malta Enterprise's grant offering also includes laboratory space at the Malta Life Sciences Park, key for further research and development.

We are tremendously proud to see the confidence and support that has been generated in the MaltaHip project and look forward to seeing the continued journey towards fully-fledged public use.

To read the full LinkedIn post from Garland Surgical, use the link here.

Share: Share on Twitter Share on LinkedIn

17 Sep 2025 | Cohort Successes

BetaDen Accelerate Cohort 2.0 alumni FARx have secured £250k in seed investment assisted by Seed...

Read Article SHARE Share on Twitter Share on LinkedIn

15 Sep 2025 | Cohort Successes

BetaDen Incubate Intake 5.0 founders Fresh Nous have been selected as finalists for the...

Read Article SHARE Share on Twitter Share on LinkedIn

10 Sep 2025 | Cohort Successes

Accelerate Cohort 8.0 alumni & Entrepreneurs in Residence, Garland Surgical have been shortlisted...

Read Article SHARE Share on Twitter Share on LinkedIn